Abstract: The mastitis control teat dip composition of the invention provides rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The compositions of the invention are made by combining an aqueous thickened liquid composition containing the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite. The materials can be combined, blended into a smooth viscous material and can be immediately contacted with the target animals. The compositions of the invention provide rapid initial kill, consistent long term kill and chemical and rheological stability.

Abstract: The present invention relates to the use of xenon as a neuroprotectant and/or as an inhibitor of synaptic plasticity. In a preferred aspect, the xenon acts as an NMDA antagonist. The present invention also provides a method of reducing the level of activation of the NMDA receptors in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon, wherein said reduction achieves neuroprotection and/or an inhibition of synaptic plasticity. A further embodiment of the invention provides a pharmaceutical composition for providing neuroprotection and/or inhibition of synaptic plasticity, together with a process for the preparation thereof.

Abstract: Cosmetic or personal care compositions comprise: a hair styling polymer having one or more groups selected from acidic functional groups, anionic groups derived from the acidic functional groups or a mixture of said groups; a partially or fully fluorinated compound having one or more groups selected from amino groups, acid salts of the amino groups or a mixture of said groups, wherein the partially or fully fluorinated compound comprises an aromatic ring; and a cosmetically acceptable diluent or carrier. The compositions are particularly effective under high humidity conditions.

Abstract: Provided, among other things, is a kit providing pre-measured amounts of components to form a fluorocarbon nutrient emulsion capable of carrying oxygen to living tissue, the kit comprising: constituent solutions, emulsions or particle compositions, which are the constituent compositions, containing pre-measured amounts of components for making the fluorocarbon nutrient emulsion, the constituent compositions comprising: poly-fluorinated, oxygen-carrying compound; a physiologically acceptable emulsifying agent effective to emulsify the polymer; a nutrient-providing effective amount of carbohydrate; nutrient-providing effective amounts of amino acids or amino acid precursors; an oncotic agent in amount effective to provide, in conjunction with the other components of the solution, a physiologically acceptable oncotic pressure; and sufficient salts and buffering agents to provide a physiological osmotic pressure and physiologically appropriate concentrations of potassium and sodium ions; wherein constituent compo

Abstract: Fluorocarbon emulsions comprising a stabilizing, particle size controlling fluorophilic/hydrophilic compound which can have the formula RF1—W—RH1  (I) wherein RF1 is a linear, branched or cyclic C2-14 fluorocarbon group; RH1 is a linear, branched or cyclic C2-18 saturated or unsaturated hydrocarbon group; and W is absent or is a bivalent species chosen from the group consisting of —O—, —S—, or various fluorinated structures. Use of the fluorophilic/lipophilic compound in the dispersions of the invention provides stable particle size and efficient emulsification. The dispersions of the invention can comprise biologically useful additive and can be used for various purposes, as oxygen carriers, contrast agents, or diagnostic agents.

Abstract: The present invention comprises methods and compositions for use in inhibiting egg production by parasitic trematode worms comprising administering to an individual in need thereof an effective amount of an agent which transiently inhibits the influx of calcium through a cell membrane calcium channel. Inhibition of egg production in the worms ameliorates many of the symptoms and pathology related to infection by trematode related diseases, including Schistosomiasis. The methods can also effect disease transmission by reducing the number of eggs released into the environment available to continue the worm life cycle.

Abstract: Benzocycloheptenes of general formula I in which R1, R2 and Y have the meanings indicated herein, have antiestrogenic activity on and are suitable for the production of pharmaceutical agents, especially for prophylaxis and therapy of osteoporosis.

Abstract: The invention concerns semi-fluorinated alkanes of the general formulae RFRH or RFRHRF, RF being a linear or branched perfluoroalkyl group and RH being a linear or branched saturated (hydrocarbon)-alkyl group.

Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWAs). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.

Abstract: A topical skin protectant formulation containing a barrier cream and a reactive moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA's). The topical skin protectant offers a barrier property and a reactive moiety that serves to neutralize chemical warfare agents into less toxic agents.

Abstract: This invention relates to a non-aqueous fluorocarbon composition for use in magnetic resonance imaging (MRI) or radiographic imaging (X-ray or computed tomography), particularly imaging of the gastrointestinal (GI) tract; an improved fluorocarbon composition with enhanced contrast effects in the GI tract; a fluorocarbon composition having improved palatability; a fluorocarbon composition for delivering drugs or bioactive agents; improved preparations for radiographic imaging or MRI; methods for producing and using such preparations; methods for improving the palatability of non-aqueous liquids; and methods for improving imaging.

Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWAs). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.

Abstract: A hyperthermic treatment of lung cancer in a patient and delivering therapeutic or diagnostic biological agents to airway surfaces, where preselected pulmonary air passages adjoining pulmonary tissues comprising malignant cells are temporarily filled and then heating adjoining pulmonary tissues comprising the malignant cells to a temperature in a specified range by transmitting ultrasound through the liquid-filled pulmonary passages of a specific frequency. Also disclosed is an apparatus for applying the ultrasound at the appropriate frequency to the interior surfaces of a bodily cavity for diagnostic and therapeutic treatment.

Abstract: A method of preserving tissue by placing the tissue in a media containing pure perfluorocarbon is provided. Also provided is a tissue preserving media including storage media and pure perfluorocarbon. A method of making media by adding pure perfluorocarbon to the media is provided. A method of preserving tissue by oxygenating the storage media by adding pure perfluorocarbons to the media is also provided.

Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA's). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.

Abstract: A topical skin protectant formulation containing a barrier cream and an active hybrid organic-inorganic polysilsesquioxane material for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA's). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.

Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.

Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA's). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.

Abstract: A topical skin protectant formulation containing a barrier cream and a active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWAs). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.

Abstract: Methods for the diagnosis and treatment of articular disorders comprising the use of fluorocarbons are disclosed. The methods provide for the introduction of a fluorocarbon into an articular region to replace or augment natural synovial fluid. The introduced fluorocarbons, which may be in various forms including liquids, gels or emulsions, provide articular lubrication and cushioning which is effective for the treatment of disorders such as osteoarthritis and rheumatoid arthritis. Additionally, the methods of the present invention may be used to provide high resolution articular images, reduce articular inflammation and introduce bioactive agents to the articular region.

Abstract: A topical skin protectant formulation containing a barrier cream and an active moiety for protecting warfighters and civilians against all types of harmful chemicals, specifically chemical warfare agents (CWA's). The topical skin protectant offers a barrier property and an active moiety that serves to neutralize chemical warfare agents into less toxic agents.

Abstract: This invention describes the new benzocycloheptenes of general formula I 1

Abstract: Skin protection agents such as topical compositions which can prevent the passage of toxic chemicals through the skin, such as barrier creams. Formulations may contain hexamethylene tetramine or derivatives or analogues thereof, which react with alkylating agents such as sulfur mustard, and which are suitable for formulation into topical compositions. The formulations additionally may contain perfluorinated polymeric compounds which are effective barrier compounds for a range of toxic chemicals.

Abstract: A fluorohydrocarbon compound of formula RF—C2H4—O—CO—RH, in which RF is a perfluorinated alkyl group and RH is an alkyl group, in and/or for the preparation of a stable emulsion containing at least one fatty phase and one aqueous phase. The invention also relates to the use of the same compound as a stabilizing agent for an emulsion containing at least one fatty phase and one aqueous phase. Another subject of the invention is the use of such a compound as an essential component of the fatty phase of an emulsion and emulsions containing such a fatty phase. Another subject of the invention is a composition comprising such an emulsion.

Abstract: Compositions of perfluorocarbons and methods of using these compositions for subcutaneous fat removal. A version of the composition also contains local anesthetic and/or vasoconstrictors. The composition is in association with a pharmacuetical carrier. The composition is for use in liposuction techniques. Also provided is a method for subcutaneous removal of lipid or fat cells from a patient using the composition.

Abstract: The present invention relates to the use of xenon as an NMDA antagonist. In particular, the invention relates to a method of treatment comprising modulating the activity of an NMDA receptor in a mammal, the method comprising modulating the activity of the NMDA receptor by administering to the mammal a therapeutically effective amount of xenon. In a further aspect, the invention provides a process for the preparation of a pharmaceutical composition suitable for modulating the activity of an NMDA receptor.

Abstract: Methods of delivering a therapeutic or diagnostic agent in a perfluorochemical liquid carrier are provided. In preferred embodiments, the disclosed methods use compositions in the form of an emulsion or a dispersion for delivery of a biological agent to the pulmonary air passages.

Abstract: The present invention relates to protection agents, in particular to topical compositions such as barrier creams which can prevent the passage of toxic chemicals and chemical warfare agents through the skin. Formulations contain hexamethylene tetramine derivatives or analogues thereof and perfluorinated polymeric compounds.

Abstract: The present invention provides a process for making transfer resistant make-up or sun-screen cosmetic compositions containing particles, which process includes introducing at least one volatile polyorganohalogen solvent, the halogen atom being fluorine, as an anti-transfer agent.

Abstract: Storage stable fluorocarbon emulsions having a continuous aqueous phase and a discontinuous fluorocarbon phase, in which the fluorocarbon phase comprises a major amount of a first fluorocarbon or fluorocarbon mixture, and a minor amount of a second fluorocarbon or fluorocarbon mixture, in which the second fluorocarbon has a molecular weight greater than that of the first fluorocarbon and the second fluorocarbon includes a lipophilic moiety in its structure, whereby the second fluorocarbon serves to promote particle size stability in the emulsion while simultaneously providing favorably short organ retention times when administered to animals in vivo.

Abstract: A cosmetic containing fluorine-containing oil represented by the following formula do not inhibit the oil repellency of powder treated with a fluorine-containing compound, is excellent in affinity for the skin, and is inexpensive.

Abstract: Fluorocarbon emulsions comprising a stabilizing, particle size controlling fluorophilic/hydrophilic compound which can have the formulaR.sub.F.sup.1 --W--R.sub.H.sup.1 (I)whereinR.sub.F.sup.1 is a linear, branched or cyclic C.sub.2-14 fluorocarbon group;R.sub.H.sup.1 is a linear, branched or cyclic C.sub.2-18 saturated or unsaturated hydrocarbon group; andW is absent or is a bivalent species chosen from the group consisting of --O--, --S--, or various fluorinated structures. Use of the fluorophilic/lipophilic compound in the dispersions of the invention provides stable particle size and efficient emulsification. The dispersions of the invention can comprise biologically useful additive and can be used for various purposes, as oxygen carriers, contrast agents, or diagnostic agents.

Abstract: This invention provides a method of treating or preventing neoplastic diseases. The method comprises adminstering to a host in need of such treatment or prevention an effective amount of a Vitamin D.sub.3 analog of the Formula I wherein:X is H.sub.2 or CH.sub.2 ;Y is hydrogen, hydroxy or fluorine;Z is hydroxy;R.sub.1 and R.sub.2 are a (C.sub.1 -C.sub.4) alkyl or fluoroalkyl, or R.sub.1 and R.sub.2 together with C.sub.25 form a (C.sub.3 -C.sub.6) cycloalkyl or cyclofluoroalkyl;R.sub.3 and R.sub.4 are a (C.sub.1 -C.sub.4) alkyl or fluoroalkyl, or R.sub.3 and R.sub.4 together with C.sub.25' form a (C.sub.3 -C.sub.6)cycloalkyl or cyclofluoroalkyl;A is a single bond or a double bond;B.sub.1 is a single bond, an E-double bond, a Z-double bond or a triple bond; andB.sub.2 is a single bond, an E-double bond, a Z-double bond or a triple bond; or a prodrug thereof.

Abstract: A method for analyzing the ADME/PK properties of a mixture of compounds is (1) perfusing an animal or organ with a perfluorocarbon emulsion blood substitute, (2) administering the mixture of test compounds, (3) withdrawing an aliquot of the perfusate, (4) disrupting the emulsion, and (5) analyzing the aqueous phase of the perfusate for the concentration of test compounds.

Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation and in particular to a pharmaceutical aerosol formulation which comprises (a) particulate medicament; (b) at least one sugar; and (c) a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.

Abstract: Storage stable fluorocarbon emulsions having a continuous aqueous phase and a discontinuous fluorocarbon phase, in which the fluorocarbon phase comprises a major amount of a first fluorocarbon or fluorocarbon mixture, and a minor amount of a second fluorocarbon or fluorocarbon mixture, in which the second fluorocarbon has a molecular weight greater than that of the first fluorocarbon and the second fluorocarbon includes a lipophilic moiety in its structure, whereby the second fluorocarbon serves to promote particle size stability in the emulsion while simultaneously providing favorably short organ retention times when administered to animals in vivo.

Abstract: The invention relates to a film-forming composition, which may be used as a mascara, an eye-liner, a nail varnish or a lacquer, in an aqueous medium, containing, in dispersed form, at least one film-forming material and a fluoro copolymer resulting from the copolymerization of at least a first fluorovinyl monomer and at least a second monomer of formula (A): ##STR1## where R.sub.1 represents a hydrogen atom or a C.sub.1 to C.sub.4 alkyl radical and R.sub.2 represents a C.sub.1 to C.sub.6 alkyl radical, a C.sub.2 to C.sub.4 hydroxycarbon radical or a radical --(CH.sub.2).sub.p --NH--R.sub.3, where R.sub.3 represents a C.sub.1 to C.sub.6 alkyl or a cycloalkyl and p is an integer ranging from 1 to 4.

Abstract: The present invention involves perfluoro compound emulsions including nitric oxide, their preparation and their use. These emulsions provide a new source of nitric oxide. Such nitric oxide-containing emulsions may be used for the administration of nitric oxide to individuals in need thereof. Individuals in need of nitric oxide administration can include those suffering from hypertension, preeclampsia and a number of other situations where an increased blood flow, for example, is desirable. In addition, given the long use of perfluoro compound emulsions as blood substitutes, the present invention provides a relatively safe mode for administering and distributing nitric oxide-without potential negative side effects such as toxicities due to drug metabolites.

Abstract: A method for the acceleration of tissue growth using continuous fluorocarbon liquid-based positive pressure is disclosed, whereby significant increase in tissue growth is achieved.

Abstract: Cosmetic skin or hair care compositions containing a liquid, inert, hydrophobic fluorocarbon infused with carbon dioxide. The compositions increase blood flow to the skin, thus increasing endogenous oxygen and nutrient delivery to the skin.

Abstract: Perfluorotetramethylcyclohexane shows improved properties for use in biological gas exchange, both as a blood substitute and as perfluorocarbon for intra-pulmonary applications. The material has an adequately low vapor pressure to completely avoid causing hyperinflated lung damage and to increase the interval between required applications. However, the compound has a sufficiently high vapor pressure to produce acceptably brief residence time within the body. A method has been developed for using this novel compound to accelerate the exhalation of very low vapor pressure compounds such as perfluorophenanthrene from the lungs. The addition of perfluorotetramethylcyclohexane, along with perfluorophenanthrene, greatly increases the rate at which the perfluorophenanthrene is exhaled.

Abstract: Fluorinated hydrocarbon compounds have formula (I):R.sub.F --(CH.sub.2).sub.n --X--?C.sub.3 H.sub.5 (OH)!--(Y).sub.x --R.sub.H ,in which C.sub.3 H.sub.5 (OH) represents structures (Ia) or (Ib): ##STR1## R.sub.F is a perfluorinated C.sub.4 -C.sub.20 alkyl radical or a mixture of perfluorinated C.sub.4 -C.sub.20 radicals; R.sub.H is a straight or branched C.sub.1 -C.sub.22 alkyl radical or a mixture of straight or branched C.sub.1 -C.sub.22 alkyl radicals or an aryl or aralkyl radical; n is from 0 to 4; X stands for O, S, ##STR2## x stands for 0 or 1; Y stands for O, S, (a) or (b); with the proviso that when X.dbd.S, (a) or (b), Y is not S, (a) or (b). The use of said compounds as amphiphilic compounds, the method of preparing them, and the cosmetic compositions containing them are also disclosed.

Abstract: A method of assisting a mammal having a lung disorder to breathe ambient gas normally, i.e., without the assistance of a ventilator. The method includes providing an animal having a lung disorder, such as surfactant deficiency, stiff lung, or hyperinflated lung syndrome, and instilling a minimum effective dose of a perfluorochemical liquid or emulsion through the trachea for coating the alveolar sacs of a lung of the mammal. The preferred perfluorochemicals have a very low vapor pressure to avoid inducing hyperinflated lung syndrome and are supplied in a minimum effective dosage sufficient to coat the inner lung surfaces. The perfluorochemicals are permeable to the ambient gas and reside substantially permanently within the alveolar sacs without inducing hyperinflated lung syndrome. The liquid is instilled in an amount sufficient to enable the animal to breathe the ambient gas normally with O.sub.2 /CO.sub.2 blood gas exchange. Effective coating of the lungs with a small (generally <0.

Abstract: A method for reducing the inflammatory response in tissues of a patient, by contacting the tissue with an effective, inflammation-reducing amount of a liquid or gaseous fluorocarbon.

Abstract: Biocompatible fluorocarbon emulsions are utilized to inhibit the removal of endogenously produced nitric oxide from the bloodstream, and to thereby inhibit vascular stenosis, vasoconstriction, and any other physiological condition or disorder arising in whole or in part from a deficiency of endogenous nitric oxide.

Abstract: Stable emulsions of highly fluorinated organic compounds for use as oxygen transport agents, "artificial bloods" or red blood cell substitutes and as contrast agents for biological imaging. The emulsions comprise a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly soluble in water, a surfactant and water.

Abstract: This invention is directed to a method of attenuating or preventing the adverse side-effects of a perfluorochemical (PFC) emulsion on the hemostatic system and serum chemistry of an animal. The method includes intravenously administering a corticosteroid to an animal prior to intravenous administration of a PFC emulsion, in an amount sufficient to improve the adverse effects of the PFC upon the hemostatic system and serum triglyceride/enzyme levels of the animal. After administration of the corticosteroid, the PFC emulsion is administered intravenously. Preferably, the corticosteroid is dexamethasone, and the PFC is perfluorodichlorooctane.

Abstract: Stable emulsions of highly fluorinated organic compounds for use as oxygen transport agents, "artificial bloods" or red blood cell substitutes and as contrast agents for biological imaging. The emulsions comprise a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly soluble in water, a surfactant and water.

Abstract: Creams formed from about 35% to about 50% fine particulates of certain poly(tetrafluoroethylene) (PTFE) resins dispersed in perfluorinated polyether oils having viscosities from about 20 cSt to about 350 cSt afford good protection against chemical warfare agents such as sulfur mustard (HD), lewisite (L), sulfur mustard/Lewisite mixtures (HL), pinacolyl methylphosphonofluoridate (soman or GD), thickened soman (TGD) and O-ethyl S-2-diisopropylaminoethyl methylphosphonothiolate (vx).

Abstract: Nonaqueous thixotropic drug delivery vehicles for use in aqueous physiological systems are disclosed comprising a substantially homogeneous dispersion of at least one suspending aid in a nonaqueous perfluorocarbon or fluorinated silicone liquid carrier. Pharmaceutical compounds may be incorporated to provide thixotropic pharmaceutical compositions having improved delivery profiles and high drug localization. The thixotropic compositions act as free-flowing, drop-instillable liquids upon the application of stress yet behave as a visco-elastic material when at rest. Due to these thixotropic properties the pharmaceutical compositions have improved bioavailability, are capable of low dose volume delivery, and do not degrade the incorporated therapeutic or diagnostic compounds making them well suited for multidose packaging and administration.